March 15, 2024Open Access

Platelet-to-lymphocyte ratio predicts tumor response and survival of patients with hepatocellular carcinoma undergoing immunotherapies

Key Points

Key points are not available for this paper at this time.

Abstract

Lymphocyte-related factors were associated with survival outcome of different types of cancers. Nevertheless, the association between lymphocytes-related factors and tumor response of immunotherapy remains unclear.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Wang et al. (Fri,) studied this question.

synapsesocial.com/papers/68e73cb8b6db6435876b61b9 https://doi.org/https://doi.org/10.1016/j.intimp.2024.111863

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma2020 · 7,254 citations
2Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes2014 · 135 citations
3Clinical significance of tumor-infiltrating lymphocytes in breast cancer2016 · 858 citations
4Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab2017 · 1,025 citations
5Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies2022 · 36 citations

Bookmark

View Full Paper